title: [Investigation of epiphora following S-1 therapy].
abstract: We report the frequency of lacrimal passage disorder and the outcomes of treatment. This retrospective study was performed on 55 cases that were treated with S-1 for at least 1 month. We asked patients about ocular symptoms. An ophthalmic surgeon examined all patients and diagnosed lacrimal passage disorder in 6 of 55 patients (12. 5%). The mean dose of S- 1 was 10, 300 mg, and the average period to onset of lacrimal passage disorder was 5. 7 months. The causes of epiphora included occlusion/stenosis of lacrimal canaliculus, occlusion of lacrimal puncta and stenosis of nasolacrimal duct. Lacrimal surgery was performed in all 6 patients and epiphora improved. Lacrimal passage disorder may result from systemic treatment of patients with S-1. Symptoms of lacrimal passage disorder improved with early detection and treatment by insertion of a silicone tube.
authors.affiliation: Dept. of Surgery, Fukui Prefectural Hospital.
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Kitamura
authors.forename: Tamon
authors.initials: T
authors.lastname: Miyanaga
authors.forename: Hisatou
authors.initials: H
authors.lastname: Shin
authors.forename: Manami
authors.initials: M
authors.lastname: Fujita
authors.forename: Manami
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yagi
authors.forename: Homare
authors.initials: H
authors.lastname: Ito
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Asaumi
authors.forename: Yasumitsu
authors.initials: Y
authors.lastname: Hirano
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Hayashida
authors.forename: Kazunari
authors.initials: K
authors.lastname: Maeda
authors.forename: Koji
authors.initials: K
authors.lastname: Ota
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hayashi
authors.forename: Kenji
authors.initials: K
authors.lastname: Douden
authors.forename: Masakazu
authors.initials: M
authors.lastname: Hattori
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hashidume
authors.forename: Tsugihisa
authors.initials: T
authors.lastname: Sasaki
mesh_terms: D000368:Aged; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007766:Lacrimal Apparatus Diseases / Q000139:chemically induced* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010094:Oxonic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D005641:Tegafur / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid